Skip to main content
. Author manuscript; available in PMC: 2024 Jun 15.
Published in final edited form as: J Immunol. 2023 Jun 15;210(12):1925–1937. doi: 10.4049/jimmunol.2200731

Figure 5. Prime-boost immunization regimen with rBCG-ChD6 and rChimera reduced weight loss in SARS-CoV-2 infected K18-hACE2 murine model.

Figure 5.

A) Schematic representation of K18-hACE2 mice (n = 5–7) prime-boost vaccination. Mice were immunized subcutaneously at day 0 with PBS, BCG WT or rBCG-ChD6 (s.c.). At day 30, mice were boosted with formulations containing PBS or rChimera with Alum. SARS-CoV-2 challenge was performed intranasally at day 50 and lungs were harvested at day 56. Results are representative of two independent experiments. B) Mice were observed for the following six days and relative body weight is represented. Statistical analyses were performed using 2-way ANOVA followed by the Bonferroni post-hoc test. An asterisk represents statistical difference when rBCG-ChD6/rChimera+Alum group (indicated by black circles connected by straight lines) was compared to PBS/PBS+Alum (indicated by white circles connected by straight lines), # when it is compared to PBS/rChimera+Alum (indicated by black triangles connected by dotted lines) and & when it is compared to BCG WT/rChimera+Alum (indicated by black squares connected by dashed lines) (p value < 0.05).